Ce
Cerevel (AbbVie)
Cambridge MAFounded 2018400 employees
Private CapbiotechAcquiredCNS
Platform: Neuroscience
Market Cap
N/A
All Drugs
3
Clinical Trials
8
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Zanulemzoparlimab | CER-4966 | Phase 1 | 2 | JAK2 | NBNSCLC | ||
| Ivomavacamten | CER-5058 | Phase 1/2 | 2 | BET | AsthmaPTSD | ||
| CER-4594 | CER-4594 | Phase 3 | 4 | TROP-2 | RACeliac |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (8)